Eli Lilly and Company $LLY Shares Acquired by Dohj LLC

Dohj LLC lifted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 266.9% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,152 shares of the company’s stock after acquiring an additional 838 shares during the quarter. Dohj LLC’s holdings in Eli Lilly and Company were worth $956,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in LLY. WestEnd Advisors LLC lifted its holdings in Eli Lilly and Company by 210.0% in the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock worth $26,000 after buying an additional 21 shares in the last quarter. Wealth Preservation Advisors LLC acquired a new position in Eli Lilly and Company in the 1st quarter worth $27,000. Citizens National Bank Trust Department lifted its holdings in Eli Lilly and Company by 180.0% in the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock worth $35,000 after buying an additional 27 shares in the last quarter. Financial Gravity Asset Management Inc. acquired a new position in Eli Lilly and Company in the 1st quarter worth $40,000. Finally, TD Capital Management LLC lifted its holdings in Eli Lilly and Company by 129.2% in the 1st quarter. TD Capital Management LLC now owns 55 shares of the company’s stock worth $46,000 after buying an additional 31 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, Director Jamere Jackson acquired 200 shares of the stock in a transaction that occurred on Friday, August 8th. The stock was acquired at an average price of $639.56 per share, with a total value of $127,912.00. Following the transaction, the director directly owned 9,402 shares in the company, valued at approximately $6,013,143.12. This represents a 2.17% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Gabrielle Sulzberger bought 117 shares of the firm’s stock in a transaction on Tuesday, August 12th. The stock was purchased at an average price of $641.18 per share, with a total value of $75,018.06. Following the transaction, the director owned 2,703 shares in the company, valued at $1,733,109.54. The trade was a 4.52% increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 4,514 shares of company stock worth $2,894,841. 0.13% of the stock is owned by company insiders.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $845.55 on Thursday. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $937.00. The firm has a 50-day simple moving average of $738.69 and a 200 day simple moving average of $766.57. The company has a market cap of $800.28 billion, a PE ratio of 55.26, a P/E/G ratio of 1.18 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating analysts’ consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter in the prior year, the firm earned $3.92 EPS. The company’s revenue for the quarter was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, sell-side analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on LLY. Hsbc Global Res upgraded shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a report on Wednesday, August 27th. DZ Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 14th. Berenberg Bank reiterated a “hold” rating and issued a $830.00 price objective (down previously from $970.00) on shares of Eli Lilly and Company in a report on Wednesday, September 17th. Daiwa Capital Markets lowered shares of Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 target price on the stock. in a research note on Sunday, August 17th. Finally, Wall Street Zen lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research note on Saturday, September 20th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have assigned a Hold rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus target price of $943.00.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.